These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11385184)

  • 1. Antiarrhythmic agents in facilitating electrical cardioversion of atrial fibrillation and promoting maintenance of sinus rhythm.
    Marcus GM; Sung RJ
    Cardiology; 2001; 95(1):1-8. PubMed ID: 11385184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
    Naegeli B; Straumann E; Bertel O
    Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C; Mouly S; Longas-Tejero MA; Bergmann JF
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005049. PubMed ID: 17943835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
    Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
    Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C; Longas-Tejero MA; Bergmann JF; Belmin J
    Cochrane Database Syst Rev; 2012 May; (5):CD005049. PubMed ID: 22592700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
    Lafuente-Lafuente C; Valembois L; Bergmann JF; Belmin J
    Cochrane Database Syst Rev; 2015 Mar; (3):CD005049. PubMed ID: 25820938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation.
    Van Gelder IC; Tuinenburg AE; Schoonderwoerd BS; Tieleman RG; Crijns HJ
    Am J Cardiol; 1999 Nov; 84(9A):147R-151R. PubMed ID: 10568674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment.
    Hayashi M; Tanaka K; Kato T; Morita N; Sato N; Yasutake M; Kobayashi Y; Takano T
    J Cardiovasc Electrophysiol; 2005 Jul; 16(7):740-7. PubMed ID: 16050832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug and electrical therapy of supraventricular tachyarrhythmias].
    Heisel A; Jung J; Schieffer H
    Z Kardiol; 2000; 89 Suppl 3():68-74. PubMed ID: 10810788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
    Boriani G; Diemberger I; Biffi M; Martignani C; Branzi A
    Drugs; 2004; 64(24):2741-62. PubMed ID: 15563247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological approaches in the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Delpón E
    Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results.
    Sung RJ
    Card Electrophysiol Rev; 2003 Sep; 7(3):300-3. PubMed ID: 14739733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.
    Crijns HJ
    Drugs; 2005; 65(12):1651-67. PubMed ID: 16060699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of symptomatic atrial fibrillation.
    Haghi D; Schumacher B
    Am J Cardiovasc Drugs; 2001; 1(2):127-39. PubMed ID: 14728042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment with antiarrhythmic drugs for elective electrical cardioversion of atrial fibrillation: a systematic review and network meta-analysis.
    Um KJ; McIntyre WF; Mendoza PA; Ibrahim O; Nguyen ST; Lin SH; Duceppe E; Rochwerg B; Healey JS; Koziarz A; Lengyel AP; Bhatnagar A; Amit G; Chu VA; Whitlock RP; Belley-Côté EP
    Europace; 2022 Oct; 24(10):1548-1559. PubMed ID: 35654763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of pharmacologic cardioversion of atrial fibrillation by Class I drugs.
    Allessie MA; Wijffels MC; Dorland R
    J Cardiovasc Electrophysiol; 1998 Aug; 9(8 Suppl):S69-77. PubMed ID: 9727679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary approach to electrical and pharmacological cardioversion of atrial fibrillation.
    Rajagopalan B; Curtis AB
    Postgrad Med; 2012 Nov; 124(6):26-35. PubMed ID: 23322136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic management of atrial fibrillation: established and emerging options.
    Kalus JS
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
    Lafuente-Lafuente C; Mouly S; Longás-Tejero MA; Mahé I; Bergmann JF
    Arch Intern Med; 2006 Apr; 166(7):719-28. PubMed ID: 16606807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid therapy of atrial fibrillation.
    Santini M; Pignalberi C; Ricci R; Calò L
    Ital Heart J; 2002 Oct; 3(10):571-8. PubMed ID: 12478814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.